A Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Mutated Nucleophosmin 1 (NPM1) Gene
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 21 May 2018 Biomarkers information updated
- 01 May 2013 New trial record